RxDoctor Payments DataLook up a doctor →

Rajat Walia, MD

Pulmonary Disease · Phoenix, AZNPI 1699710046

Payments from drug & device makers

$1,916,217in general payments, 2019–2025

Across 1,321 payments — averaging $1450.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$553K
  • Grifols Therapeutics LLC$312K
  • Boehringer Ingelheim$243K
  • Takeda Pharmaceuticals U.S.A., Inc.$195K
  • Sanofi US Services Inc.$193K
  • Astellas Pharma US Inc$115K
  • plus $306K from 37 others
$2,627in research payments, 2019–2025

Across 27 payments — averaging $97.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$2K
  • Sanofi US Services Inc.$1K

What the payments were for

  • Consulting fees$102,61114%
  • Speaking & faculty fees$504,17067%
  • Travel & lodging$119,11516%
  • Food & beverage$21,9683%
  • Education$2980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,916,217 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$83,833
Medicare patients
637
Services billed
3,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlassiaAlpha-1-Proteinase Inhibitor12$129,303
CresembaIsavuconazonium Sulfate13$98,688
Mycophenolate Mofetil12$3,844
Itraconazole27$3,804
Valganciclovir Hcl15$3,661
Tacrolimus16$980
Omeprazole27$883
Azithromycin29$621
Prednisone40$411
Pravastatin Sodium14$320
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$240
Montelukast Sodium19$237
Alendronate Sodium12$197
Metoprolol Tartrate12$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Glassia$195,329$129,30312 claims
Astellas Pharma US IncCresemba$114,661$98,68813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →